2007
Pharmacokinetics of Antimony in Children Treated for Leishmaniasis with Meglumine Antimoniate
Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG. Pharmacokinetics of Antimony in Children Treated for Leishmaniasis with Meglumine Antimoniate. The Journal Of Infectious Diseases 2007, 195: 602-608. PMID: 17230422, DOI: 10.1086/510860.Peer-Reviewed Original ResearchConceptsPharmacokinetics of antimonyMeglumine antimoniateDrug exposureIntramuscular meglumine antimoniateWeight-adjusted clearancePeak concentrationPotential clinical relevanceTime-concentration curveLower peak concentrationsAntimonial therapyPharmacokinetic differencesCutaneous leishmaniasisClinical relevanceChildren 3Day 20Clearance rateAntimoniateLeishmaniasisAdultsChildrenSecond groupFirst groupPharmacokineticsDaysExposure
2006
Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection
Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection. The Journal Of Infectious Diseases 2006, 193: 1375-1383. PMID: 16619185, DOI: 10.1086/503371.Peer-Reviewed Original ResearchConceptsTreatment failureMeglumine antimoniatePrimary resistanceAntimonial drugsSecondary resistanceDrug resistanceHuman Leishmania infectionsEffective immune responseAnthroponotic visceral leishmaniasisAmerican cutaneous leishmaniasisAntimonial therapyStandard treatmentCutaneous diseaseLeishmania infectionTherapeutic responseImmune responseCutaneous leishmaniasisVisceral leishmaniasisAnthroponotic transmissionResistant organismsEffective doseIntracellular amastigotesSusceptible strainsAntimoniatePatients